MedTrace Logo

Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)

NCT00630500 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2015-07-28

No results posted yet for this study

Summary

A 24-week placebo-controlled parallel group multicentre trial to study the safety and efficacy of memantine in patients with dementia associated with Parkinson's disease and dementia with Lewy bodies. It is hypothesized that memantine will be safe and well tolerated, and more effective than placebo.

Conditions

  • Dementia Associated With Parkinson's Disease
  • Dementia With Lewy Bodies

Interventions

DRUG

Memantine

Tablets, 5 or 10 mg, twice daily

DRUG

Placebo

Tablets corresponding to 5 or 10 mg, twice daily, 6 months

Sponsors & Collaborators

  • King's College London

    collaborator OTHER

  • Lund University

    collaborator OTHER

  • Helse Stavanger HF

    lead OTHER_GOV

Principal Investigators

  • Dag Aarsland, MD, PhD · Helse Stavanger HF

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2009-02-28
Completion
2009-03-31

Countries

  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00630500 on ClinicalTrials.gov